Professor Oliver Bandmann MD PhD
Professor of Movement Disorders Neurology
Honorary Consultant Neurologist
Department of Neuroscience
Sheffield Institute for Translational Neuroscience
University of Sheffield
385a Glossop Road
Telephone: +44 (0) 114 2222237
Fax: +44 (0)114 2222290
2002-present: University of Sheffield/Royal Hallamshire Hospital, Sheffield, UK
My research focuses on movement disorders, in particular Parkinson´s Disease (PD) but also Huntington´s Disease, Wilson Disease and dystonia. I’m particularly interested in working towards disease-modifying therapy for PD which would slow down disease progression.
The main areas of research within my group are as follows:
1. Mitochondrial dysfunction and compound screen with identification of neuroprotective compounds as candidates for disease-modifying treatment in Parkinson’s Disease:
For interested members of the public: Please have a look at the official University of Sheffield press release for more information on this project. You may also be interested in listening to a BBC interview with Prof Bandmann.
Fig1. The image shows a fibroblast from a patient with Parkinson’s Disease due to mutations in the parkin gene. The fibroblast has been stained to show the mitochondria in the cell. We see increased branching and interconnectedness of the mitochondrial network in the fibroblasts from patients with parkin mutations compared to controls; this change in morphology of the mitochondria correlates with changes in function.
2. Bench to bedside – early clinical trials in Parkinson’s disease
There is emerging evidence of a “Parkinson Epidemic” with a predicted global doubling in the number of people with Parkinson’s from 6 million to 12 million between 2015 and 2014 (PMID:30584159).
We have now taken UDCA as the top hit of our drug screen into an early clinical trial, called the UP study (short for: UDCA in Parkinson’s disease). The UP study will predominantly focus on investigating the safety and tolerability of UDCA in PD. However, we will also use novel techniques (in particular 31P-MR-Spectroscopy and sensor-based objective quantification of motor impairment) to gain some insight into the neuroprotective potential of UDCA.
MR Spectroscopy of a human brain with focussed analysis of the basal ganglia (the area most affected in Parkinson’s disease)
My group is also participating in two other multicentre neuroprotection trials, testing statins and antibodies against alpha-synuclein for their neuroprotective effect.
This link will take you to a webpage of the Cure Parkinson’s Trust - it provides additional information on UDCA for Parkinson’s:
You may also find this video interesting during which we describe our journey from the bench at SITraN to the clinical trial carried out at the NIHR-funded Clinical Research facility at the Royal Hallamshire Hospital:
3. Zebrafish as a new vertebrate animal model for Parkinson’s Disease:
We subsequently demonstrated that Parkin-deficient zebrafish share key features with human parkin-mutant Parkinson’s Disease patients, namely mitochondrial dysfunction and loss of dopaminergic neurons. Most recently, we have identified up-regulation of TIGAR as novel mechanism leading to mitochondrial dysfunction and dopaminergic cell loss in PINK1 deficiency. Inhibition of TIGAR prevents loss of dopaminergic neurons by normalizing mitochondrial function. TIGAR is therefore a promising novel target for disease-modifying therapy in early onset Parkinson’s Disease. We are now also using zebrafish to study genetic risk factors for sporadic Parkinson’s and how they may interact with ageing.
For interested members of the public: Please have a look at the
4. Mitochondrial biomarkers in Parkinson’s Disease:
5. Huntington's Disease (HD)
6. Wilson Disease (WD)
In close collaboration with the Wilson disease patient self-help group, we have helped to establish a UK-wide, interdisciplinary Wilson disease network. This network will hopefully allow us to develop national standards for the care of Wilson disease patients and facilitate future research projects.
|Teaching Interests||I was the Dept Neuroscience Undergraduate Teaching Lead/Director for Teaching and Learning for 15 years (2002-2017). I was also the University of Sheffield BMedSci Programme Director for 5 years (2013-2018). I twice won the “Consultant Teacher of the Year" award of the Sheffield Medical Student Society MedSoc.
I continue to contribute to all undergraduate phases of our MBChB course and also contribute to SITRaN-based MSc courses.
I am now the academic training lead for the STH Neuroscience Directorate and also the Training Lead for our NIHR-funded Sheffield Neuroscience BRC.
1984-1991: Bavarian Scholarship for highly gifted students
|Prinicipal Funding Sources||
The UP Study is predominantly funded by the JP Moulton Foundation, but also supported by Cure Parkinson’s UK and the Sheffield Neuroscience BRC.
My research is also supported by the Medical Research Council (MRC), the Michael J Fox Foundation (MJFF) and the University of Sheffield. In the past, I’ve also had substantial funding from Parkinson’s UK.
|Members of Research Group||
Clinical Fellows: Dr Tom Payne, Dr Emily Reed
Co-supervision with Dr Heather Mortiboys:
Postdoctoral scientist: Dr Helen Rowland
Glucocerebrosidase 1 deficient Danio rerio mirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death. Keatinge M, Bui H, Menke A, Chen YC, Sokol AM, Bai Q, Ellett F, Da Costa M, Burke D, Gegg M, Trollope L, Payne T, McTighe A, Mortiboys H, de Jager S, Nuthall H, Kuo MS, Fleming A, Schapira AH, Renshaw SA, Highley JR, Chacinska A, Panula P, Burton EA, O'Neill MJ, Bandmann O. Hum Mol Genet. 2015 Dec 1;24(23):6640-52. doi: 10.1093/hmg/ddv369. Epub 2015 Sep 16.
UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2(G2019S) carriers and in vivo. Mortiboys H, Furmston R, Bronstad G, Aasly J, Elliott C, Bandmann O. Neurology. 2015 Sep 8;85(10):846-52. doi: 10.1212/WNL.0000000000001905. Epub 2015 Aug 7. PMID: 26253449
TigarB causes mitochondrial dysfunction and neuronal loss in PINK1 deficiency. Flinn LJ, Keatinge M, Bretaud S, Mortiboys H, Matsui H, De Felice E, Woodroof HI, Brown L, McTighe A, Soellner R, Allen CE, Heath PR, Milo M, Muqit MM, Reichert AS, Köster RW, Ingham PW, Bandmann O. Ann Neurol. 2013 Dec;74(6):837-47. doi: 10.1002/ana.23999. PMID: 24027110
Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease. Mortiboys H, Aasly J, Bandmann O. Brain. 2013 Oct;136(Pt 10):3038-50. doi: 10.1093/brain/awt224. Epub 2013 Sep 2.
A genetic study of Wilson's disease in the United Kingdom. Coffey AJ1, Durkie M, Hague S, McLay K, Emmerson J, Lo C, Klaffke S, Joyce CJ, Dhawan A, Hadzic N, Mieli-Vergani G, Kirk R, Elizabeth Allen K, Nicholl D, Wong S, Griffiths W, Smithson S, Giffin N, Taha A, Connolly S, Gillett GT, Tanner S, Bonham J, Sharrack B, Palotie A, Rattray M, Dalton A, Bandmann O. Brain. 2013 May;136(Pt 5):1476-87. doi: 10.1093/brain/awt035. Epub 2013 Mar 21.
For a full list of publications, see also: